Clinical Trial Update: The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom

View source ↗

Summary

This clinical trial update describes an ongoing study evaluating the role of PCSK9 in kidney damage within nephrotic syndrome and notes that recruitment is ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Nephrotic Syndrome

Snippet

Sponsor: Kolding Sygehus | Conditions: Hyperlipidemias, Nephrotic Syndrome | Status: RECRUITING